ADA Insights: Strategic T1D Screening and Management

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

An expert reviews risk factors for type 1 diabetes including autoimmune disease and family history, along with the role of autoimmune antibody screening to enable early disease detection, though access to these specialized tests can be limited.

A medical professional discusses the process of diagnosis of type 1 diabetes, including challenges that emerge during screening and considerations for improving the pathway.

Robert Gabbay, MD, PhD, discusses research showing that early intervention with a recent FDA-approved therapy can delay the onset of type 1 diabetes by an average of 2-3 years.

A professional discussion on diagnosing type 1 diabetes based on autoimmune antibodies, oral glucose tolerance test results, fasting glucose, and hemoglobin A1C levels.

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.